| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Stetz Gary S. II serves as a Director at CTRVP. Across recent SEC filings that breaks down to 1 buy and 0 sells. Those positions are worth an estimated $650 at current prices.
The biggest single holding is CTRVP (~$650) as Director. Net of sales, the recent Form 4 record there shows accumulation of 500,000 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Aug 3, 2026 | CTRVP Hepion Pharmaceuticals, Inc. | Director | Buy | 500,000 | $0.05 | $25,000.00 | New |